Söndag 22 December | 11:57:15 Europe / Stockholm
Svenska | English

Recipharm

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-23 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning RECI B 0.00 SEK
2021-05-11 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-10 - Extra Bolagsstämma 2021
2021-02-18 - Bokslutskommuniké 2020
2021-01-28 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-27 - Kvartalsrapport 2020-Q2
2020-05-13 - X-dag ordinarie utdelning RECI B 0.00 SEK
2020-05-12 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-25 - Kvartalsrapport 2019-Q2
2019-05-14 - X-dag ordinarie utdelning RECI B 1.25 SEK
2019-05-13 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-07-25 - Kvartalsrapport 2018-Q2
2018-05-15 - X-dag ordinarie utdelning RECI B 0.00 SEK
2018-05-14 - Årsstämma
2018-04-27 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-07-25 - Kvartalsrapport 2017-Q2
2017-05-11 - X-dag ordinarie utdelning RECI B 1.50 SEK
2017-05-10 - Årsstämma
2017-04-27 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-31 - Kapitalmarknadsdag 2016
2016-07-22 - Kvartalsrapport 2016-Q2
2016-05-10 - Extra Bolagsstämma 2016
2016-04-29 - X-dag ordinarie utdelning RECI B 1.50 SEK
2016-04-28 - Årsstämma
2016-04-28 - Kvartalsrapport 2016-Q1
2016-02-24 - Bokslutskommuniké 2015
2015-11-05 - Kvartalsrapport 2015-Q3
2015-07-23 - Kvartalsrapport 2015-Q2
2015-05-08 - X-dag ordinarie utdelning RECI B 1.25 SEK
2015-05-07 - Årsstämma
2015-05-07 - Kvartalsrapport 2015-Q1
2015-02-19 - Bokslutskommuniké 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-11-07 - Analytiker möte 2014
2014-09-11 - Extra Bolagsstämma 2014
2014-08-14 - Kvartalsrapport 2014-Q2
2014-05-08 - Kvartalsrapport 2014-Q1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Recipharm är verksamma inom läkemedelsindustrin. Bolaget drivs idag via flertalet affärssegment med störst inriktning mot outsourcingtjänster. Utöver är bolaget delaktiga i utveckling av läkemedel, produktion av material till kliniska prövningar samt utveckling av produktionsmetoder. Störst verksamhet återfinns inom den nordiska marknaden. Huvudkontoret ligger i Stockholm.
Recipharm AB: Recipharm applies for delisting of shares and summons to extraordinary general meeting
2021-02-15 15:30:00

The Board of Directors of Recipharm AB (publ) ("Recipharm") applies for delisting of its B-shares from Nasdaq Stockholm. An extraordinary general meeting to appoint new board members will be held on 10 March 2021.

On 14 December 2021, Roar BidCo AB ("Roar BidCo") announced a public offer to the shareholders of Recipharm. Roar BidCo today declared the offer unconditional. Roar BidCo controls approximately 95.1 per cent of the total number of shares in Recipharm and has initiated compulsory redemption of the remaining shares.

Based on the information above, and at the request of Roar BidCo, the board of directors of Recipharm has applied for delisting of Recipharm's B-shares from Nasdaq Stockholm. The last day of trading on Nasdaq Stockholm will be announced as soon as such a date has been decided and communicated to Recipharm by Nasdaq Stockholm.

At the request of Roar BidCo, an extraordinary general meeting in Recipharm will be held on 10 March 2021 in order to appoint new board members of Recipharm. A notice to the extraordinary general meeting will be sent out separately.

Carnegie Investment Bank AB (publ) and Stifel Nicolaus Europe Limited acted as financial advisers and Vinge and Simmons & Simmons as legal advisers to Recipharm in connection with the public offer.

 

For further information, please contact:
Anders G. Carlberg, chairman of the independent board of Recipharm
By phone: +46 70-543 75 76

The information was submitted for publication, through the agency of the contact person set out above, at 3:30 pm CET on 15 February 2021.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com 

Källa Cision
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden